Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert
Mainz Biomed (NASDAQ:MYNZ) has expanded its collaboration with Liquid Biosciences to leverage AI for optimizing biomarker selection in PancAlert, its next-generation pancreatic cancer detection test. The partnership aims to enhance early-stage disease detection, potentially combining PancAlert with Mainz Biomed's colorectal cancer screening product.
The first phase of collaboration showed promising results, leading to a second phase that will include microbiome biomarkers analyzed with Microba Life Sciences in 2023. The companies plan to complete this analysis in Q4 2024. Pancreatic cancer, with a global mortality rate of 466,000 annually, has one of the lowest survival rates among major cancers, emphasizing the critical need for early detection methods.
Mainz Biomed (NASDAQ:MYNZ) ha ampliato la sua collaborazione con Liquid Biosciences per sfruttare l'IA nell'ottimizzazione della selezione dei biomarcatori per PancAlert, il suo test di rilevamento del cancro pancreatico di nuova generazione. L'obiettivo della partnership è migliorare la rilevazione precoce della malattia, potenzialmente combinando PancAlert con il prodotto di screening per il cancro del colon-retto di Mainz Biomed.
La prima fase della collaborazione ha mostrato risultati promettenti, portando a una seconda fase che includerà biomarcatori del microbioma analizzati con Microba Life Sciences nel 2023. Le aziende pianificano di completare questa analisi nel quarto trimestre del 2024. Il cancro pancreatico, con un tasso di mortalità globale di 466.000 all'anno, ha uno dei tassi di sopravvivenza più bassi tra i tipi di cancro principali, sottolineando l'urgente necessità di metodi di rilevazione precoce.
Mainz Biomed (NASDAQ:MYNZ) ha ampliado su colaboración con Liquid Biosciences para aprovechar la IA en la optimización de la selección de biomarcadores en PancAlert, su prueba de detección de cáncer pancreático de nueva generación. El objetivo de la asociación es mejorar la detección temprana de la enfermedad, potencialmente combinando PancAlert con el producto de detección de cáncer colorrectal de Mainz Biomed.
La primera fase de la colaboración mostró resultados prometedores, lo que llevó a una segunda fase que incluirá biomarcadores del microbioma analizados con Microba Life Sciences en 2023. Las empresas planean completar este análisis en el cuarto trimestre de 2024. El cáncer pancreático, con una tasa de mortalidad global de 466,000 al año, tiene una de las tasas de supervivencia más bajas entre los principales tipos de cáncer, lo que enfatiza la necesidad crítica de métodos de detección temprana.
Mainz Biomed (NASDAQ:MYNZ)는 AI를 활용하여 PancAlert에서 바이오마커 선택 최적화를 위한 Liquid Biosciences와의 협력을 확장했습니다. 이 차세대 췌장암 검출 테스트를 통해 조기 질병 탐지 개선을 목표로 하며, PancAlert를 Mainz Biomed의 대장암 검진 제품과 결합할 가능성이 있습니다.
협력의 첫 번째 단계에서 유망한 결과가 나타나 2023년에 Microba Life Sciences와 분석된 미생물군 바이오마커를 포함하는 두 번째 단계로 이어졌습니다. 두 회사는 2024년 4분기까지 이 분석을 완료할 계획입니다. 췌장암은 매년 466,000명의 전 세계 사망률을 기록하고 있으며, 주요 암 중 생존율이 가장 낮은 암 중 하나로 조기 발견 방법의 절실한 필요성을 강조합니다.
Mainz Biomed (NASDAQ:MYNZ) a élargi sa collaboration avec Liquid Biosciences pour tirer parti de l'IA afin d'optimiser la sélection des biomarqueurs dans PancAlert, son test de détection du cancer du pancréas de nouvelle génération. Le partenariat vise à améliorer la détection précoce de la maladie, en combinant potentiellement PancAlert avec le produit de dépistage du cancer colorectal de Mainz Biomed.
La première phase de collaboration a montré des résultats prometteurs, menant à une deuxième phase qui comprendra des biomarqueurs de microbiome analysés avec Microba Life Sciences en 2023. Les entreprises prévoient de compléter cette analyse au quatrième trimestre de 2024. Le cancer du pancréas, avec un taux de mortalité mondial de 466 000 par an, a l'un des taux de survie les plus bas parmi les principaux cancers, soulignant le besoin critique de méthodes de détection précoce.
Mainz Biomed (NASDAQ:MYNZ) hat seine Zusammenarbeit mit Liquid Biosciences ausgeweitet, um KI zur Optimierung der Biomarker-Auswahl in PancAlert, seinem Test zur frühzeitigen Erkennung von Bauchspeicheldrüsenkrebs der nächsten Generation, zu nutzen. Ziel der Partnerschaft ist es, die Früherkennung von Krankheiten zu verbessern, möglicherweise indem PancAlert mit dem Screening-Produkt für kolorektalen Krebs von Mainz Biomed kombiniert wird.
Die erste Phase der Zusammenarbeit zeigte vielversprechende Ergebnisse, was zu einer zweiten Phase führte, die 2023 Biomarker des Mikrobioms umfasst, die zusammen mit Microba Life Sciences analysiert werden. Die Unternehmen planen, diese Analyse im vierten Quartal 2024 abzuschließen. Bauchspeicheldrüsenkrebs hat mit einer weltweiten Sterberate von 466.000 pro Jahr eine der niedrigsten Überlebensraten unter den häufigsten Krebsarten, was den dringenden Bedarf an frühen Erkennungsmethoden unterstreicht.
- Expansion of collaboration with Liquid Biosciences to optimize PancAlert biomarker selection
- Promising results from the first phase of AI-driven biomarker analysis
- Potential to combine PancAlert with existing colorectal cancer screening product
- Planned completion of expanded biomarker analysis in Q4 2024
- None.
Insights
The collaboration between Mainz Biomed and Liquid Biosciences for PancAlert development is a significant step in early pancreatic cancer detection. The promising results from the first phase, using AI-driven biomarker analysis, suggest potential for a groundbreaking screening test. This could be a game-changer for pancreatic cancer, which has a
The planned expansion to include microbiome biomarkers in the second phase could further enhance the test's accuracy. If successful, combining PancAlert with Mainz's colorectal cancer screening product could create a powerful multi-cancer early detection tool, potentially revolutionizing cancer diagnostics and improving patient outcomes significantly.
The partnership leverages Liquid Biosciences' EMERGE platform, an advanced AI technology for biomarker selection optimization. This application of AI in medical diagnostics represents a cutting-edge approach to complex biological data analysis. The successful first phase, using a single algorithm, demonstrates the potential of AI in enhancing diagnostic accuracy.
The planned extension of the AI algorithm in the second phase could lead to even more sophisticated analysis. This iterative process of AI model refinement is important for developing highly accurate diagnostic tools. The integration of diverse data types, including microbiome biomarkers, showcases the versatility and power of AI in healthcare innovation, potentially accelerating the development of life-saving diagnostic technologies.
This collaboration could significantly impact Mainz Biomed's (NASDAQ:MYNZ) market position and financial outlook. Developing a first-in-class pancreatic cancer screening test addresses a huge unmet medical need, potentially opening a lucrative market. With pancreatic cancer causing
The potential to combine PancAlert with Mainz's existing colorectal cancer screening product could create a valuable diagnostic portfolio, enhancing the company's competitive edge. However, investors should note that the project is still in R&D, with completion of the second phase expected in Q4 2024. While promising, it's important to consider the time and investment required for clinical trials and regulatory approvals before potential commercialization.
PancAlert is a Next-Generation Pancreatic Cancer Detection Test in Mainz Biomed’s Research and Development Pipeline – Promising Results of First Analysis
BERKELEY, Calif. and MAINZ, Germany, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the expansion of its collaboration with Liquid Biosciences to Mainz Biomed’s next-generation detection test for pancreatic cancer. The companies will leverage Liquid Biosciences proprietary AI analysis technology platform (EMERGE) to expand and optimize the selection of novel biomarkers for PancAlert.
The recently completed first phase of the collaboration included the evaluation of biomarkers from the Company’s research program co-funded by the German Federal Ministry for Education and Research, and applied a single algorithm developed by Liquid Biosciences using its EMERGE platform. The results of this feasibility analysis were promising, leading the Company and Liquid Biosciences to believe that a PancAlert diagnostic test could, in the future, be combined with Mainz Biomed’s colorectal cancer screening product. The Company and Liquid Biosciences plan to continue with the second phase of the collaboration, for which the evaluation of biomarkers will be expanded to include the microbiome biomarkers that were analyzed in collaboration with Microba Life Sciences in 2023, as well as an extension of the AI algorithm. The companies plan to complete this analysis in the fourth quarter of 2024.
“We are excited about the collaboration with Liquid Biosciences on PancAlert, which is being developed for early-stage disease detection. A first-in-class screening test for pancreatic cancer would be a major achievement in the fight of this devastating disease,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “Liquid Biosciences is already a key partner for our next generation colorectal cancer screening test. Expanding our partnership will allow us to leverage the power of AI also for the detection of this deadly form of cancer.”
Pancreatic cancer is a malignant neoplasm of the pancreas with one of the highest mortality rates of all major cancers. Each year, about 466,000 lives are taken globally, and it’s the seventh leading cause of cancer-related death worldwide.1 It has one of the lowest survival rates of any cancer, with typically late detection and poor outcomes with standard of care treatment(s). The 5-year overall survival rate is approximately
References
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PMID: 33538338. The online GLOBOCAN 2020 database is accessible at http://gco.iarc.fr/, as part of IARC’s Global Cancer Observatory.
- National Cancer Institute, Surveillance, Epidemiology and End Results Program (SEER). Cancer Stat Facts: Pancreatic Cancer. July 2021. https://seer.cancer.gov/statfacts/html/pancreas.html
- Rawla P, Sunkara T, Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol. 2019;10(1):10-27. doi:10.14740/wjon1166
Please visit Mainz Biomed’s official website for investors at mainzbiomed.com/investors/ for more information
Please follow us to stay up to date:
LinkedIn
X (Previously Twitter)
Facebook
About Mainz Biomed NV
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlert® is marketed across Europe and the United Arab Emirates. The Company is currently running a pivotal FDA clinical study for US regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. To learn more, visit mainzbiomed.com or follow us on LinkedIn, Twitter and Facebook.
About Liquid Biosciences
Liquid Biosciences is the leader in quantitative AI for diagnostics and biopharma. We radically reduce diagnostic and drug development risk, time, and cost. Our Emerge quantitative AI platform agnostically discovers and models the nonlinear dynamics of biology, behavior, and circumstances that drive patient outcomes. Emerge has produced superior accuracy, novel insights, and explainability in every head-to-head comparison with other AI methods. Liquid Biosciences has completed over 250 major analytic programs across 50 diseases, for major biopharma firms, diagnostic companies, and world-class research institutions. For more information about Liquid Biosciences, visit www.liquidbiosciences.com.
For media inquiries
MC Services AG
Anne Hennecke/Caroline Bergmann
+49 211 529252 20
mainzbiomed@mc-services.eu
For investor inquiries, please contact info@mainzbiomed.com
Forward-Looking Statements
Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on April 9, 2024. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.
FAQ
What is Mainz Biomed's (MYNZ) latest development in pancreatic cancer detection?
When does Mainz Biomed (MYNZ) plan to complete the second phase of PancAlert biomarker analysis?
What is the potential impact of Mainz Biomed's (MYNZ) PancAlert test?
How does the collaboration between Mainz Biomed (MYNZ) and Liquid Biosciences work?
